Compare Diageo plc (DEO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs GeneDx Holdings Corp — how do they compare? Diageo plc trades at $94.15 (market cap $53.05B), while GeneDx Holdings Corp trades at $82.2 (market cap $2.44B). The key difference: Diageo plc is far larger — about 21.7× GeneDx Holdings Corp's market cap, and Diageo plc pays a 3.5% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| DEO | WGS | |
|---|---|---|
Market Cap | $53.05B | $2.44B |
Sector | Technology | Technology |
52-Week High | $115.33 | $167.51 |
52-Week Low | $72.47 | $34.51 |
Enterprise Value | $72.54B | $2.48B |
Dividend Yield | 3.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $93.96, down 3.24% today, with mixed technical signals showing bullish moving averages but overbought RSI readings. The company reported FY2026 results with organic sales declining 2% but operating profit increasing 2% through cost savings. Recent news highlights a $1 billion cost-cutting plan and strategic reset under new CEO Dave Lewis, driving investor optimism despite North American weakness.
The outlook remains cautiously optimistic with analyst consensus leaning buy (49%) as cost savings and cash generation initiatives offset regional challenges. Key risks include persistent North American sales pressure and execution risks on the turnaround plan, while valuation metrics suggest premium pricing relative to historical levels.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
